The aesthetic and broader healthcare landscape is entering a new phase. Since the end of 2025, the focus is clearly shifting toward subtle enhancement, individualized care, and minimally invasive solutions. For any medical device company, biotech player, or pharmaceutical industry stakeholder, these changes are not just trends—they are reshaping product development, manufacturing, and clinical practice.

Patients today are no longer seeking dramatic transformations. Instead, they favor treatments that enhance their natural features while preserving facial harmony. This evolution is influencing every aesthetic medical device company, pushing innovation toward more refined, adaptable solutions. Treatments now integrate skin quality, facial structure, and long-term tissue health. This holistic mindset also extends to fields such as orthopedics and oral tissue regeneration products, where regenerative approaches are gaining traction.

One of the most significant advances lies in the development of highly specialized hyaluronic acid and sodium hyaluronate formulations. These next-generation dermal filler products are designed for specific anatomical zones, enabling practitioners to customize treatments with greater accuracy.

This evolution directly impacts the design of the injectable product and its delivery system. The combination of optimized hydrogel properties with advanced prefilled syringe technologies ensures consistent performance and improved safety.

In particular, hydrogel prefilled syringe manufacturing has become a critical area of expertise for any CDMO supporting the pharmaceutical and medical device sectors. For example, SyrhaTech is a Swiss CDMO specialized in hyaluronic acid-based injectable medical devices. The precision of filling, control of sterility, and compatibility with sterile hypodermic syringes are essential performance requirements for SyrhaTech.

The structuring of the profession is accelerating. With the introduction of new academic certifications in aesthetic medicine, practitioners must now meet higher training standards. This shift strengthens the credibility of the sector and reassures patients.

Examples include the ‘European Inter-University Diploma in Reparative and Aesthetic Facial Injections’ in France (Université Paris Cité), the ‘Postgraduate Certificate (PgCert) in Aesthetic Medicine’ in the United Kingdom (Queen Mary University of London), and the ‘Master in Aesthetic Medicine and Therapeutics’ in Italy (University of Camerino).

For a medical device company, this also means aligning with more demanding expectations in terms of product performance, clinical data, and regulatory compliance. Quality is no longer a differentiator—it is a baseline.

The global healthcare market for aesthetic procedures is expanding steadily, with growth rates exceeding 7% annually from 2025 onward. Non-surgical procedures, particularly injectables, represent a substantial share of this expansion.
This dynamic benefits multiple stakeholders:

The demand for reliable, scalable production of injectable product formats continues to rise, reinforcing the strategic role of experienced partners.

As complexity increases, outsourcing to specialized partners becomes a key success factor. A CDMO with expertise in hydrogel, hyaluronic acid, and prefilled syringe technologies can significantly accelerate time-to-market while ensuring compliance with international standards.

Whether supporting an aesthetic medical device company or a broader pharmaceutical industry player, these partners bring:

The aesthetic medicine sector is evolving toward greater sophistication, combining science, safety, and personalization. Innovations in hyaluronic acid, hydrogel, and prefilled syringe systems are at the heart of this transformation.

Adapting to these trends means investing in precision, quality, and advanced manufacturing capabilities. In this context, partnering with an experienced CDMO such as SyrhaTech is more than a strategic choice—it is a competitive advantage in a rapidly growing global market.

Do you have a development project or an injectable product to manufacture?
Partner with a trusted Swiss CDMO and bring your innovation to market with confidence.

Contact our team to discuss your project.